Travere Therapeutics (TVTX) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Travere Therapeutics (TVTX) over the last 10 years, with Q4 2024 value amounting to $43.6 million.
- Travere Therapeutics' Accumulated Depreciation & Amortization rose 1304.18% to $43.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was $43.6 million, marking a year-over-year increase of 1304.18%. This contributed to the annual value of $43.6 million for FY2024, which is 1304.18% up from last year.
- According to the latest figures from Q4 2024, Travere Therapeutics' Accumulated Depreciation & Amortization is $43.6 million, which was up 1304.18% from $38.5 million recorded in Q4 2023.
- In the past 5 years, Travere Therapeutics' Accumulated Depreciation & Amortization ranged from a high of $43.6 million in Q4 2024 and a low of $12.7 million during Q4 2021
- Moreover, its 5-year median value for Accumulated Depreciation & Amortization was $24.6 million (2020), whereas its average is $28.0 million.
- Per our database at Business Quant, Travere Therapeutics' Accumulated Depreciation & Amortization crashed by 4814.27% in 2021 and then surged by 8596.46% in 2023.
- Travere Therapeutics' Accumulated Depreciation & Amortization (Quarter) stood at $24.6 million in 2020, then tumbled by 48.14% to $12.7 million in 2021, then skyrocketed by 62.55% to $20.7 million in 2022, then skyrocketed by 85.96% to $38.5 million in 2023, then increased by 13.04% to $43.6 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $43.6 million for Q4 2024, versus $38.5 million for Q4 2023 and $20.7 million for Q4 2022.